Evaluation of rivastigmine efficacy in treatment of major depressive disorder: a randomized double blind controlled trial

Amir Mohammad Shabani; Samaneh Farnia; Naemeh Tabaraee; Seyed Davood hoseini; Narjes Hendouei

Evaluation of rivastigmine efficacy in treatment of major depressive disorder: a randomized double blind controlled trial

7^th Edition of International Conference on Family Medicine & Primary Care

February 22-24, 2018 Paris, France

Amir Mohammad Shabani, Samaneh Farnia, Naemeh Tabaraee, Seyed Davood hoseini and Narjes Hendouei

Mazandaran University of Medical Sciences, Iran

Scientific Tracks Abstracts: Quality in Primary Care

Abstract:

Background & Aim: Rivastigmine, a reversible inhibitor of acetylcholinesterase, which is used in treatment of mild to moderate Alzheimerâ�?�?s disease. In recent years, several studies have been conducted on the use of this drug in psychiatric disorders (e.g., dementia, Lewy body and autism), but few reports are exist associated with the use of rivastigmine in the treatment of depression in the absence of cognitive impairment. In this study, the aim was to determine whether adding rivastigmine to the standard therapeutic regimen of patients with major depression could improve some aspects of the symptom burden or not. Materials & Methods: Twenty patients with major depression were recruited randomly and then received either 3 milligram daily with sertraline regimen or with sertraline regimen only. Hamilton depression scale and Wechsler Memory were evaluated in patients at the baseline, end of first, second and third months. P values of less than 0.05 were considered significant. Results: During the study, the Hamilton Depression Scale score changes within groups were F (2/61, 47/1) = 35/8, p<0/001, Partial eta squared=0/66. But the changes of Hamilton Depression Scale scores werenâ�?�?t significant between groups (p value=0.2). The changes of Wechsler Memory Scale were 13�?±4.7 (95% CI=-9.616.3) and 8.07�?±4.9 (95%CI=-0.8-10.6) in rivastigmine and control group respectively (p=0.01) and there was a significant difference in first, third and Seventh Wechsler Memory Subscale scores (p=0.05, p=0.007, p<0.001 respectively). Conclusion: In this study, use of rivastigmine compared with placebo in MDD patients had significant effects on the reduction memory dysfunction, especially in personal information, orientation and auditory memory.